More Company News

Hutchison China MediTech

Application to list in Hong Kong and proposed global offering
15 Apr 2019Read More

Hutchison China MediTech

Initiation of Surufatinib China Phase IIb/III in Unresectable or Metastatic BTC
29 Mar 2019Read More

Hutchison China MediTech

Oral Presentations on Savolitinib Lung Cancer Programs at AACR
28 Mar 2019Read More

Hutchison China MediTech

2018 Annual Report and Notice of AGM
21 Mar 2019Read More

Hutchison China MediTech

2018 Final Results and Clinical Update
11 Mar 2019Read More

Hutchison China MediTech

Preliminary Phase II savolitinib/Imfinzi PRCC data at 2019 ASCO GU
12 Feb 2019Read More

Hutchison China MediTech

Savolitinib lung cancer progress and kidney cancer strategy update
20 Dec 2018Read More

Hutchison China MediTech

Amendment to 2013 Eli Lilly Fruquintinib License and Collaboration Deal
20 Dec 2018Read More

Hutchison China MediTech

Multiple Collaborations to Evaluate PD-1 Combinations with Surufatinib and Fruquintinib
29 Nov 2018Read More

Hutchison China MediTech

First Commercial Launch of Fruquintinib Capsules (Elunate)
26 Nov 2018Read More

1 2
Return to Hutchison China MediTech
© 2019 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).